Obesity Phenotypes, Diabetes, and Cardiovascular Diseases
Key finding
Established that obesity phenotypes vary widely in metabolic risk, highlighting how targeted fat metabolism interventions like NNMT inhibition could address the specific metabolic dysfunction driving cardiovascular disease.
Key takeaways
- Not all obesity is the same — where your body stores fat matters more than the number on the scale.
- Certain obesity types carry much higher risk for heart disease and diabetes.
- Targeted approaches to fat metabolism, like NNMT inhibitors, may help address the root metabolic issues.
Study breakdown
Obesity is one of the most significant risk factors for cardiovascular disease and diabetes, yet research increasingly shows that not all obesity carries the same metabolic risk. This influential review by Piché, Tchernof, and Després, published in Circulation Research, explored how different obesity phenotypes relate to diabetes and cardiovascular disease outcomes.
The authors analyzed the existing body of evidence on obesity classification, examining how factors like visceral fat distribution, ectopic fat deposition, and adipose tissue dysfunction contribute to metabolic risk profiles. They assessed the clinical relevance of distinguishing between metabolically healthy and metabolically unhealthy obesity phenotypes.
The findings revealed that obesity phenotypes vary significantly in their association with cardiometabolic risk. Visceral and ectopic fat accumulation, rather than total body fat alone, emerged as the primary drivers of insulin resistance, dyslipidemia, and cardiovascular events. This distinction is critical because it suggests that interventions targeting specific fat metabolism pathways may be more effective than general weight loss strategies.
For the field of metabolic health, this review reinforces the importance of precision approaches to obesity treatment. Compounds that target specific metabolic enzymes involved in fat storage and energy balance, such as NNMT inhibitors like 5-Amino-1MQ, align well with this phenotype-driven approach by addressing the underlying metabolic dysfunction rather than simply reducing total body weight.
Read the full study on PubMed for complete methodology and data.
View full study on PubMedPMID: 32437302
More 5-Amino-1MQ research
Obesity and hypertension
Seravalle G, Grassi G · Pharmacological research
Relevance of body composition in phenotyping the obesities
Salmón-Gómez L, Catalán V, Frühbeck G, et al. · Reviews in endocrine & metabolic disorders
The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function
Goossens GH · Obesity facts
Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis
Marcelin G, Silveira ALM, Martins LB, et al. · The Journal of clinical investigation
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
Heide J, Bilecz AJ, Patnaik S, et al. · Nature
Curious how this research applies to your goals?
Book a free consult with Dr. TaylorDisclaimer: This summary is educational only and is not medical advice. For complete methodology and data, refer to the original publication on PubMed. Always consult a qualified healthcare provider before making medical decisions.